RQ BIOTECHNOLOGY LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  -100%

  £12,059,429 → £0

• Cash

  -31.2%

  £15,827,176 → £10,892,690

• Net assets

  -21.7%

  £15,439,251 → £12,091,286

  first positive since 2022

• Employees

  +9.1%

  11 → 12

  highest in 3 filed years

• Operating profit

  -193.6%

  £5,605,640 → -£5,247,270

• Profit before tax

  -185.4%

  £5,509,735 → -£4,703,269

• Wages

  -15.2%

  £1,754,229 → £1,487,610

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

RSM UK Audit LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The financial statements have been prepared on a going concern basis, which assumes that the Company will continue as a going concern for the foreseeable future being a period of at least twelve months from the date of approval of these financial statements. Anticipated expenditure in accordance with the business plan for the full twelve months from the date of approval of these financial statements are sufficiently covered from cash reserves.”

Significant events

• “In April 2024 the Company demerged the business associated with the out license for clinical development antibodies. The management and obligations under the license agreement with Astra Zeneca are now undertaken by RQBio Covid Limited, a commonly controlled entity.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.